NEW YORK, November 1, 2016
NEW YORK, November 1, 2016 /PRNewswire/ --
Ahead of today's trading session, Stock-Callers.com takes notice of these Medical Appliances and Equipment equities: Globus Medical Inc. (NYSE: GMED), Align Technology Inc. (NASDAQ: ALGN), ZELTIQ Aesthetics Inc. (NASDAQ: ZLTQ), and Accuray Inc. (NASDAQ: ARAY). These companies are part of the Healthcare sector which fell for the seventh time in eight sessions on Monday, October 31, 2016, with the NYSE Health Care Index dropping 0.3%, and shares of health care companies in the S&P 500 declining about 0.5% as a group. Learn more about these stocks by downloading their free report at:
Audubon, Pennsylvania headquartered Globus Medical Inc.'s stock finished Monday's session 0.94% lower at $22.13. A total volume of 805,986 shares was traded, which was above their three months average volume of 630,040 shares. The Company's shares are trading below their 50-day moving average by 3.17%. Furthermore, shares of Globus Medical, which focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders, have a Relative Strength Index (RSI) of 41.37.
On October 25th, 2016, Globus Medical announced the introduction of the INDEPENDENCE MIS™ System, an integrated ALIF plate-spacer system designed to simplify implantation and fixation of a commonly challenging procedure. The INDEPENDENCE MIS™ system features advanced instruments that deploy three pre-loaded anchors through a small protected corridor no larger than the implant itself. INDEPENDENCE MIS™ streamlines the anterior procedure into three simple steps: inserting the implant, deploying the anchors, and locking the anchors. The free research report on GMED is available at:
On Monday, shares in San Jose, California headquartered Align Technology Inc. ended the session at $85.92, up 0.88%. The stock recorded a trading volume of 1.38 million shares, which was above its three months average volume of 764,520 shares. The Company's shares have gained 30.48% since the start of this year. The stock is trading 8.10% above its 200-day moving average. Moreover, shares of Align Technology, which designs, manufactures, and markets a system of clear aligner therapy, intra-oral scanners, and computer-aided design and computer-aided manufacturing (CAD/CAM) digital services for use in dentistry, orthodontics, and dental records storage in the US and internationally, have an RSI of 36.93.
On October 03rd, 2016, research firm Robert W. Baird downgraded the Company's stock rating from 'Outperform' to 'Neutral', issuing a target price of $96 per share.
On October 11th, 2016, Align Technology announced that one-week aligner wear is now recommended for all Invisalign Full, Teen, and Assist products, instead of two-week aligner wear for each stage of Invisalign treatment. Continued Invisalign product innovation including "G-Series" features, SmartTrack aligner material, and clinically proven treatment predictability, allow the company to recommend one-week wear. Align's recommendation is also based on clinical analysis of more than 200 in-progress Invisalign cases, the experiences of numerous Invisalign providers, as well as the unanimous endorsement of its North American Clinical Advisory Board for the use of one-week aligner wear. The complimentary report on ALGN can be downloaded at:
Pleasanton, California headquartered ZELTIQ Aesthetics Inc.'s stock ended yesterday's session 0.33% lower at $33.10 with a total trading volume of 592,240 shares. The Company's shares have advanced 16.02% on an YTD basis. The stock is trading 9.36% above its 200-day moving average. Additionally, shares of ZELTIQ Aesthetics, which engages in developing and commercializing non-invasive products for the selective reduction of fat, have an RSI of 24.08.
On October 19th, 2016, ZELTIQ® announced that it plans to release its Q3 2016 financial results on November 9th, 2016 after the market close. The company will hold a conference call on November 9th, 2016 at 4:30 p.m. ET to discuss the results. Visit us today and download our complete research report on ZLTQ for free at:
At the close on Monday, shares in Sunnyvale, California headquartered Accuray Inc. recorded a trading volume of 810,930 shares, which was above their three months average volume of 647,170 shares. The stock finished 2.00% lower at $4.90. The Company's shares are trading below their 200-day moving average by 10.46%. Furthermore, shares of Accuray, which designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body, have an RSI of 34.59.
On October 27th, 2016, Accuray reported that gross product orders totaled $50.3 million for Q1 FY17 compared to $64.9 million for Q1 FY16. Total revenue for Q1 FY17 was $86.5 million compared to $89.6 million in Q1 FY16. Total gross profit for Q1 FY17 was $31.3 million, or 36% of sales. Net loss was $9.9 million, or $0.12 per share, for Q1 FY17 compared to a net loss of $13.0 million, or $0.16 per share, for Q1 FY16. Get free access to your technical report on ARAY at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES :
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SAPR Newswire
Last updated on: 01/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.